Anaptysbio (ANAB)
47.94
+2.51 (5.52%)
Upcoming Events
Latest Headlines
FDA approves Jemperli for rectal cancer, benefiting AnaptysBio
October 19, 2026 2:21 PM - StreetInsider
Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer
October 19, 2026 2:18 PM - Globe NewsWire
Form 4 ANAPTYSBIO, INC For: Oct 01 Filed by: RENTON HOLLINGS
October 2, 2026 5:48 PM - SEC Filing
Form 144 ANAPTYSBIO, INC Filed by: RENTON HOLLINGS
October 1, 2026 4:08 PM - SEC Filing
AnaptysBio (ANAB) PT Lowered to $60 at JPMorgan
September 30, 2026 9:09 AM - StreetInsider
AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 524c
September 22, 2026 7:54 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on AnaptysBio (ANAB)
September 22, 2026 7:36 AM - StreetInsider
Form 10-KT ANAPTYSBIO, INC For: Jun 30
September 21, 2026 4:24 PM - SEC Filing
Form 8-K ANAPTYSBIO, INC For: Sep 21
September 21, 2026 4:20 PM - SEC Filing
Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
September 21, 2026 4:15 PM - StreetInsider
Form 4 ANAPTYSBIO, INC For: Sep 15 Filed by: Orwin John A
September 17, 2026 4:05 PM - SEC Filing
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference
September 1, 2026 4:15 PM - StreetInsider
Wolfe Research Reiterates Outperform Rating on AnaptysBio (ANAB)
August 31, 2026 5:37 AM - StreetInsider
AnaptysBio (ANAB) PT Lowered to $70 at TD Cowen
August 25, 2026 7:37 AM - StreetInsider
Form SCHEDULE 13G/A ANAPTYSBIO, INC Filed by: Sirenia Capital Management LP
August 14, 2026 8:31 AM - SEC Filing
Form 8-K ANAPTYSBIO, INC For: Aug 11
August 11, 2026 4:05 PM - SEC Filing
Form 4 ANAPTYSBIO, INC For: Mar 12 Filed by: Lizzul Paul F.
August 7, 2026 5:13 PM - SEC Filing
Form 4 ANAPTYSBIO, INC For: Mar 12 Filed by: Faga Daniel
August 7, 2026 5:12 PM - SEC Filing
Form 8-K ANAPTYSBIO, INC For: Jul 28
July 30, 2026 4:05 PM - SEC Filing
Full Article List
